Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ADAG | Adagene Inc.

Index- P/E- EPS (ttm)-1.84 Insider Own10.59% Shs Outstand42.99M Perf Week-8.51%
Market Cap55.35M Forward P/E- EPS next Y-2.01 Insider Trans0.00% Shs Float39.00M Perf Month12.17%
Income-80.00M PEG- EPS next Q-0.38 Inst Own13.70% Short Float / Ratio0.07% / 1.15 Perf Quarter6.61%
Sales9.30M P/S5.95 EPS this Y-1.00% Inst Trans-21.09% Short Interest0.03M Perf Half Y-16.98%
Book/sh1.93 P/B0.67 EPS next Y-23.30% ROA-43.30% Target Price13.77 Perf Year-7.86%
Cash/sh3.35 P/C0.38 EPS next 5Y- ROE-59.40% 52W Range0.90 - 2.10 Perf YTD-2.64%
Dividend- P/FCF- EPS past 5Y- ROI-76.20% 52W High-38.57% Beta0.14
Dividend %- Quick Ratio2.70 Sales past 5Y- Gross Margin- 52W Low43.33% ATR0.10
Employees248 Current Ratio2.70 Sales Q/Q340.90% Oper. Margin- RSI (14)44.15 Volatility3.99% 7.28%
OptionableNo Debt/Eq0.33 EPS Q/Q19.20% Profit Margin- Rel Volume0.28 Prev Close1.33
ShortableYes LT Debt/Eq0.17 EarningsAug 31 BMO Payout- Avg Volume25.45K Price1.29
Recom1.70 SMA20-3.19% SMA50-4.86% SMA200-11.32% Volume7,170 Change-3.01%
Date Action Analyst Rating Change Price Target Change
Jun-25-21Initiated China Renaissance Buy $40.57
Mar-08-21Initiated Morgan Stanley Overweight $34
Mar-08-21Initiated Jefferies Buy $33
Mar-08-21Initiated Goldman Buy $29
Sep-07-23 10:45PM
Aug-31-23 07:32AM
May-25-23 09:40AM
09:00AM Loading…
May-04-23 09:00AM
Apr-28-23 07:00AM
Apr-18-23 09:17AM
Mar-31-23 09:40AM
Mar-28-23 04:30PM
Mar-14-23 06:00PM
Mar-05-23 07:39PM
Jan-09-23 07:00AM
Jan-05-23 04:01PM
06:30AM Loading…
Dec-16-22 06:30AM
Nov-21-22 04:05PM
Nov-10-22 09:05AM
Oct-11-22 04:03PM
Sep-10-22 04:13AM
Aug-30-22 05:25PM
Jun-29-22 04:05PM
May-26-22 09:30PM
May-12-22 07:00AM
May-02-22 06:06AM
Apr-08-22 01:09PM
Apr-03-22 02:34PM
Mar-31-22 08:30AM
Mar-17-22 10:42AM
10:00AM Loading…
Mar-16-22 10:00AM
Mar-08-22 09:21PM
Mar-02-22 08:22AM
Feb-08-22 07:00AM
Feb-02-22 04:05PM
Jan-27-22 07:00AM
Jan-19-22 07:00AM
Jan-13-22 04:00AM
Dec-22-21 04:05PM
Dec-13-21 10:23AM
Dec-06-21 01:49PM
Nov-30-21 04:01PM
Nov-29-21 04:05PM
Nov-22-21 05:05PM
Nov-09-21 04:05PM
Nov-04-21 09:24AM
Oct-27-21 08:52AM
Oct-21-21 08:00AM
Sep-17-21 12:22PM
Sep-02-21 07:45AM
Aug-26-21 07:45AM
Aug-19-21 07:37AM
Aug-12-21 07:45AM
Jul-22-21 07:45AM
Jul-12-21 10:15PM
Jul-09-21 10:47AM
Jul-07-21 07:45AM
Jun-16-21 04:49PM
May-25-21 04:05PM
May-19-21 05:05PM
Apr-13-21 07:45AM
Mar-31-21 07:45AM
Mar-29-21 07:45AM
Mar-16-21 08:05AM
Feb-11-21 10:08AM
Feb-09-21 05:18PM
Adagene Inc., a clinical stage immunotherapy company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.